John Libbey Eurotext

Epileptic Disorders

The Educational Journal of the International League Against Epilepsy

Adjunctive lacosamide for focal epilepsy: an open-label trial evaluating the impact of flexible titration and dosing on safety and seizure outcomes Volume 19, numéro 2, June 2017

Illustrations

  • Figure 1
  • Figure 2

Tableaux

Auteurs
1 IHU-ICM and Department of Neurology, Pitié-Salpêtrière Hospital, Paris
2 UCB Pharma, Colombes, France
3 UCB Pharma, Raleigh, USA
4 UCB Pharma, Brussels, Belgium
5 Neurophysiology Clinic, University Hospital La Timone (AP-HM), Marseille
6 IHU-ICM and Department of Neurosurgery, Pitié-Salpêtrière Hospital, Paris, France
* Correspondence: Michel Baulac Clinique Neurologique, Hôpital de la Pitié-Salpêtrière, 47-83 Boulevard de l’Hôpital, Paris 75013, France
  • Mots-clés : focal, seizure, dizziness, flexible dose, a ;tiepileptic, individualised, titration
  • DOI : 10.1684/epd.2017.0907
  • Page(s) : 186-94
  • Année de parution : 2017

Aims

To evaluate the safety and effectiveness of lacosamide in a real-life setting with the use of a flexible dose titration schedule and individualised maintenance doses up to the maximum approved dose of 400 mg/day.